Predicting haloperidol occupancy of central dopamine D2 receptors from plasma levels

Psychopharmacology

Volumn 149, Issue 1, 2000, Pages 1-5

  Fitzgerald, Paul B ^a   Kapur, Shitij ^a   Remington, Gary ^a   Roy, Paul ^a   Zipursky, Robert B ^a  

^a CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

Author keywords

Dopamine; Haloperidol; Human; Receptor occupancy

Indexed keywords

CARBON 11; DOPAMINE 2 RECEPTOR; HALOPERIDOL; RACLOPRIDE;

ACCURACY; ADULT; ARTICLE; CLINICAL ARTICLE; CORPUS STRIATUM; DELUSION; DOPAMINERGIC SYSTEM; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG MECHANISM; DRUG RECEPTOR BINDING; FEMALE; HUMAN; MALE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PSYCHOSIS; RECEPTOR OCCUPANCY; SCHIZOPHRENIA;

ADULT; ANTIPSYCHOTIC AGENTS; BINDING, COMPETITIVE; FEMALE; HALOPERIDOL; HUMANS; MALE; PREDICTIVE VALUE OF TESTS; RECEPTORS, DOPAMINE D2; SCHIZOPHRENIA; SCHIZOPHRENIA, PARANOID; STATISTICS; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 0034126828     PISSN: 00333158     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002139900333     Document Type: Article

References (23)

1. Baron J, Martinot J, Cambon H, Boulenger J, Poirier M, Caillard V, Blin J, Huret J, Loc'h C, Maziere B (1989) Striatal dopamine receptor occupancy during and following withdrawal from neuroleptic treatment: correlative evaluation by positron emission tomography and plasma prolactin levels. Psychopharmacology 99:463-472
2. 2 occupancy and prolactin levels in first episode psychosis. Biol Psychiatry 43:113S
3. 2 dopamine receptors in neuroleptic-naive schizophrenic patients. Arch Gen Psychiatry 47:213-219
4. 2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine: relation to extrapyramidal side-effects. Arch Gen Psychiatry 49:538-544
5. First M, Spitzer R, Gibbon M, Williams J (1995) Structured clinical interview for DSM-IV axis I disorders - clinician version. (Tertiary structured clinical interview for DSM-IV axis I disorders - clinician version). American Psychiatric Press, Washington, D.C.
6. Goyer P, Berridge M, Morris E, Semple W, ComptonToth B, Schulz C, Wong D, Miraldi F, Meltzer H (1996) PET measurements of neuroreceptor occupancy by typical and atypical neuroleptics. J Nucl Med 37:1122-1127
7. Hagberg G, Gefvert O, Bergstrom M, Wieselgren IM, Lindstrom L, Wiesel FA, Langstrom B (1998) N-[C-11]Methylspiperone PET, in contrast to [C-11]raclopride, fails to detect D-2 receptor occupancy by an atypical neuroleptic. Psychiatry Res Neuroimaging 82:147-160
8. 3H]raclopride to rat and human brain membranes. J Neurochem 55:2048-2057
9. 2 dopamine receptor characteristics in neuroleptic-naive schizophrenic patients studied with positron emission tomography. Arch Gen Psychiatry 51:116-123
10. Kapur S (1998) A new framework for investigating antipsychotic action in humans: lessons from PET imaging. Mol Psychiatry 3:135-140
11. 2 dopamine receptor occupancy of risperidone and its relationship to extrapyramidal symptoms: a PET study. Life Sci 57:PL103-PL107
12. 2 receptor occupancy with low dose haloperidol treatment: a PET study. Am J Psychiatry 153:948-950
13. 2 receptor occupancy profile of loxapine determined using PET. Neuropsychopharmacology 15:562-566
14. 2 receptor occupancy and plasma levels of low dose haloperidol: a PET study. Psychopharmacology 131:148-152
15. Limbird L (1986) Cell surface receptors: a short course on theory and methods. Kluwer, Boston
16. 2-dopamine receptor occupancy in relation to antipsychotic drug effects - a double-blind PET study of schizophrenic patients. Biol Psychiatry 33:227-235
17. 2 dopamine receptor occupancy during low-dose treatment with haloperidol decanoate. Am J Psychiatry 152:173-178
18. Pilowsky LS, Costa DC, Ell PJ, Murray RM, Verhoeff NPLG, Kerwin RW (1993) Antipsychotic medication, D(-2) dopamine receptor blockade and clinical response: a (+123)I IBZM SPET (single photon emission tomography) study. Psychol Med 23:791-797
19. 2 receptors. Life Sci 60:207-216
20. 4 receptor varies with the affinity of the competing radioligand. Eur J Pharmacol 291:59-66
21. 2 receptor reveals different densities for dopamine receptor antagonist ligands. Implications for human brain positron emission tomography. Eur J Pharmacol 227:139-146
22. Sheiner LB, Beal SL (1981) Some suggestions for measuring predictive performance. J Pharmacokinet Biopharm 9:503-512
23. Wolkin A, Brodie JD, Barouche F, Rotrosen J, Wolf AP, Smith M, Fowler J (1989) Dopamine receptor occupancy and plasma haloperidol levels. Arch Gen Psychiatry 46:482-483